Advanced

Influence of treatment with diethylstilbestrol for carcinoma of prostate on platelet aggregation and plasma lipoproteins

Agardh, Carl-David LU ; Rasmussen, F; Nilsson-Ehle, Peter LU and Gustafson, A (1986) In Urology 28(6). p.469-471
Abstract
Treatment of prostatic carcinoma with estrogens is accompanied by an increased risk for thromboembolic and cardiovascular complications. The underlying mechanisms are still unknown. Patients treated with diethylstilbestrol (DES) were compared with patients given no estrogen treatment regarding factors (platelet aggregation in vitro and plasma lipoproteins) that have been suggested to contribute to increased thrombogenesis and cardiovascular risk. The results do not show any increase in in vitro platelet aggregation in patients treated with DES compared with those given no treatment. This indicates that hyperaggregability does not contribute to the increased incidence in thromboembolic events seen in DES-treated patients. This is in... (More)
Treatment of prostatic carcinoma with estrogens is accompanied by an increased risk for thromboembolic and cardiovascular complications. The underlying mechanisms are still unknown. Patients treated with diethylstilbestrol (DES) were compared with patients given no estrogen treatment regarding factors (platelet aggregation in vitro and plasma lipoproteins) that have been suggested to contribute to increased thrombogenesis and cardiovascular risk. The results do not show any increase in in vitro platelet aggregation in patients treated with DES compared with those given no treatment. This indicates that hyperaggregability does not contribute to the increased incidence in thromboembolic events seen in DES-treated patients. This is in contrast to the increased platelet aggregation previously described in patients treated with polyestradiolphosphate + etinylestradiol. The changes in plasma lipoproteins observed during DES-treatment are generally considered beneficial from an atherogenic point of view and do not appear to cause the elevated incidence of cardiovascular disease in these patients. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Urology
volume
28
issue
6
pages
469 - 471
publisher
Elsevier
external identifiers
  • pmid:3787919
  • scopus:0023004524
ISSN
1527-9995
DOI
10.1016/0090-4295(86)90145-7
language
English
LU publication?
yes
id
f3809e6e-6963-4970-a9ba-9bea03d16de6 (old id 1103585)
date added to LUP
2008-08-11 09:33:59
date last changed
2017-01-01 05:17:38
@article{f3809e6e-6963-4970-a9ba-9bea03d16de6,
  abstract     = {Treatment of prostatic carcinoma with estrogens is accompanied by an increased risk for thromboembolic and cardiovascular complications. The underlying mechanisms are still unknown. Patients treated with diethylstilbestrol (DES) were compared with patients given no estrogen treatment regarding factors (platelet aggregation in vitro and plasma lipoproteins) that have been suggested to contribute to increased thrombogenesis and cardiovascular risk. The results do not show any increase in in vitro platelet aggregation in patients treated with DES compared with those given no treatment. This indicates that hyperaggregability does not contribute to the increased incidence in thromboembolic events seen in DES-treated patients. This is in contrast to the increased platelet aggregation previously described in patients treated with polyestradiolphosphate + etinylestradiol. The changes in plasma lipoproteins observed during DES-treatment are generally considered beneficial from an atherogenic point of view and do not appear to cause the elevated incidence of cardiovascular disease in these patients.},
  author       = {Agardh, Carl-David and Rasmussen, F and Nilsson-Ehle, Peter and Gustafson, A},
  issn         = {1527-9995},
  language     = {eng},
  number       = {6},
  pages        = {469--471},
  publisher    = {Elsevier},
  series       = {Urology},
  title        = {Influence of treatment with diethylstilbestrol for carcinoma of prostate on platelet aggregation and plasma lipoproteins},
  url          = {http://dx.doi.org/10.1016/0090-4295(86)90145-7},
  volume       = {28},
  year         = {1986},
}